Objective To study the effect of atorvastatin intensive lipid-lowering therapy on lipid metabolism

lipoprotein-associated phospholipase A2（Lp-PLA2） and prognosis of patient with coronary heart disease after coronary artery bypass grafting（CABG）. Methods Eighty patients with coronary heart disease who underwent CABG in the hospital between April 2019 and December 2020 were selected. They were divided into control group and intensive group by random number table method with 40 patients in each group. All patients were given atorvastatin lipid-lowering therapy. The doses of atorvastatin in control group and intensive group were 20mg/d and 40mg/d

respectively. Changes in ipid metabolism [total cholesterol（TC）

low-density lipoprotein cholesterol（LDL-C）

high-density lipoprotein cholesterol（HDL-C） and triglyceride（TG）] and serum Lp-PLA2 level before operation and at 1 month after operation were compared between the two groups. The incidence of major adverse cardiovascular events（MACE） was counted

and medication safety was recorded. Results The levels of TC

TG

LDL-C and Lp-PLA2 in the two groups at 1 month after operation were significantly lower than those before operation（p<0.05）

and the decreases were more significant in intensive group than in control group（p<0.05）. The proportion of patients with LDL-C decreasing by more than 50% in intensive group was significantly higher than that in control group（p<0.05）.All patients were followed up for 6 months

and the incidence of MACE was significantly lower in intensive group than in control group（p<0.05）. The incidence of adverse reactions showed no statistically significant difference between the two groups（p<0.05）. Conclusions Atorvastatin intensive lipid-lowering therapy can significantly improve lipid metabolism

regulate Lp-PLA2 level and reduce the risk of MACE in patients with coronary heart disease after CABG

with good safety.